Johnson & Johnson

J&J Targets $100 Billion in 2026 Sales Despite Stelara Patent Cliff

4 days ago talkbio0Tagged 2026, Darzalex, J&J, Johnson & Johnson, medtech, Neoplasms, Patent Cliff, Sales - occupational activity, Shockwave Medical, Stelara

Johnson & Johnson; J&J; 2026 sales; $100 billion; Stelara; patent cliff; DARZALEX; oncology; MedTech; Shockwave Medical

J&J Brushes Off MFN Impact, Forecasts $100 Billion Revenue Milestone for 2026

5 days ago talkbio0Tagged Innovative Medicine, J&J, Johnson & Johnson, medtech, MFN, Projections and Predictions, Trump drug pricing

J&J; Johnson & Johnson; MFN; Trump drug pricing; 2026 forecast; $100 billion; MedTech; Innovative Medicine

J&J-backed Cellular Origins raises $40M for cell therapy manufacturing

2 months ago talkbio0Tagged cell therapy manufacturing, Cellular Origins, Constellation platform, cyclic adenosine-5'-trimetaphosphate, Groups, Johnson & Johnson, Manufacturing, Purpura, Thrombotic Thrombocytopenic, robotic automation

Cellular Origins; Johnson & Johnson; Series A; $40 million; cell therapy manufacturing; Constellation platform; robotic automation; ATMP; TTP Group; scalable manufacturing

Johnson & Johnson Halts Phase 2 Alzheimer’s Trial After Tau Antibody Failure

2 months ago talkbio0Tagged Alzheimer 's disease, Clinical Failure, Clinical Trials, discontinued, Johnson & Johnson, posdinemab, tau-targeting antibody

Johnson & Johnson; Alzheimer’s disease; tau-targeting antibody; posdinemab; Phase 2b AuTonomy trial; clinical failure; trial discontinued

Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion to Add RIPTAC Cancer Drug Platform

2 months ago talkbio0Tagged Acquisition, clinical pipeline, Halda Therapeutics, HLD-0915, Johnson & Johnson, Malignant neoplasm of prostate, Neoplasms, RIPTAC, Targeted Protein Degradation

Johnson & Johnson; Halda Therapeutics; acquisition; RIPTAC; HLD-0915; prostate cancer; targeted protein degradation; oncology; clinical pipeline

Pharma Investment Surge in US Manufacturing Creates Major Opportunities for CDMOs

3 months ago talkbio0Tagged Advanced therapies, alpha 1-antitrypsin, Biological Factors, capital investment, CDMOs, eli lilly, Growth, Johnson & Johnson, Market, pharmaceutical manufacturing, production, supply chain, U.S.

US pharmaceutical manufacturing; CDMOs; capital investment; Johnson & Johnson; Eli Lilly; biologics; API production; supply chain; advanced therapies; market growth

Inspira Technologies Appoints Former Johnson & Johnson Executive as VP of Global Sales

3 months ago talkbio0Tagged Appointments, Arginine Vasopressin-Neurophysin II Preproprotein, board of directors, commercialization, global sales, Health care facility, Inspira Technologies, Johnson & Johnson, Leadership, Mike Hershkovitz

Inspira Technologies; Mike Hershkovitz; Johnson & Johnson; VP of Global Sales; leadership appointment; healthcare; commercialization; board of directors

Johnson & Johnson to Separate Orthopaedics Business

3 months ago talkbio0Tagged DePuy Synthes, Diastasis, Johnson & Johnson, medtech, Orthopedics

Johnson & Johnson; Orthopaedics; DePuy Synthes; MedTech; Separation

FDA Issues Warning Letter to J&J Subsidiary Over Stopper Issues and Quality Reporting at Korean Plant

4 months ago talkbio0Tagged Cautionary Warning, Incheon, Janssen Vaccines, Johnson & Johnson, Korean language, pharmaceutical manufacturing, Plants, production, quality control violations, spotty complaint reporting, United States Food and Drug Administration, vial stopper defects

FDA warning letter; Johnson & Johnson subsidiary; Janssen Vaccines; Korean production plant; vial stopper defects; quality control violations; spotty complaint reporting; good manufacturing practices; Incheon; pharmaceutical manufacturing

J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

4 months ago talkbio0Tagged Dental Plaque, deucravacitinib, IL-23 receptor antagonist, JNJ-2113, Johnson & Johnson, Myers, oral peptide, Phase 3 clinical trial, Psoriasis, skin clearance, Sotyktu

Icotrokinra; JNJ-2113; Johnson & Johnson; IL-23 receptor antagonist; Sotyktu; deucravacitinib; plaque psoriasis; Phase 3 clinical trial; skin clearance; oral peptide; Bristol Myers Squibb